ACADIA Pharmaceuticals Inc.
(NASDAQ:ACAD)
$18.44
-1.01 (-5.19%)
Open: 12:36 PM
ACAD Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
ACAD Stock Price Today
ACADIA Pharmaceuticals Inc. (ACAD) stock declined over -5.19% intraday to trade at $18.44 a share on NASDAQ. The stock opened with a loss of -0.31% at $19.39 and touched an intraday high of $19.39, falling -5.19% against the last close of $19.45. The ACADIA Pharmaceuticals Inc. in stock market went to a low of $18.48 during the session.
ACAD Stock Snapshot
$19.45
Prev. Close
3.29 Billion
Market Cap
$18.48
Day Low
$19.39
Open
161.99 Million
Number of Shares
$19.39
Day High
-
P/E ratio
-1.34
EPS (TTM)
2.57
Cash Flow per Share
4.97
Free Float in %
2.47
Book Value
335,471
Volume
Contact Details
12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
Website:https://www.acadia-pharm.com
Contact #:858 558 2871
Company Information
Employees511
Beta0.56
Sales or Revenue$517.24 Million
5Y Sales Change32.90%
Fiscal Year EndsDec. 2022
SectorHealth Care
IndustryBiotechnology
About Company
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Frequently Asked Questions
What is the current ACADIA Pharmaceuticals Inc. (ACAD) stock price?
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock price is $18.44 in the last trading session. During the trading session, ACAD stock reached the peak price of $19.39 while $18.48 was the lowest point it dropped to. The percentage change in ACAD stock occurred in the recent session was -5.19% while the dollar amount for the price change in ACAD stock was -$1.01.
ACAD's industry and sector of operation?
The NASDAQ listed ACAD is part of Biotechnology industry that operates in the broader Health Care sector. ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
Who are the executives of ACAD?
Mr. Austin D. Kim
Executive Vice President, Gen. Counsel & Sec.
Mr. Brendan P. Teehan
Executive Vice President, Chief Operating Officer & Head of Commercial
Dr. Srdjan R. Stankovic M.D., M.S.P.H.
Pres
Ms. Holly Valdiviez
Senior Vice President & Head of Sales
How ACAD did perform over past 52-week?
ACAD's closing price is 0.51% higher than its 52-week low of $12.24 where as its distance from 52-week high of $28.06 is -0.34%.
How many employees does ACAD have?
Number of ACAD employees currently stands at 511. ACAD operates from 12830 El Camino Real, Suite 400, San Diego, CA 92130, United States.
Link for ACAD official website?
Official Website of ACAD is: https://www.acadia-pharm.com
How do I contact ACAD?
ACAD could be contacted at phone #858 558 2871 and can also be accessed through its website. ACAD operates from 12830 El Camino Real, Suite 400, San Diego, CA 92130, United States.
How many shares of ACAD are traded daily?
ACAD stock volume for the day was 335,471 shares. The average number of ACAD shares traded daily for last 3 months was 1.56 Million.
What is the market cap of ACAD currently?
The market value of ACAD currently stands at $3.29 Billion with its latest stock price at $18.44 and 161.99 Million of its shares outstanding.